SCN1A and encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy: It is important to note that some of the therapies listed below relate to treatment of clinically defined syndromes (such as Dravet and Rett syndrome) regardless of the underlying genetic aetiology (e.g. Lorcaserin for Dravet syndrome), whereas other therapies are both syndrome and gene-specific therapies (e.g. STK-001 for SCN1A-related Dravet syndrome).